UCB


A rare window of affordability

10/09/26 -"After an incredible 184% share price run from November 2023 to February 2026, UCB’s shares have lost c.28% of their value. This is largely because of the pricing pressure from 1/ an agreement (from ..."

Pages
54
Language
English
Published on
10/09/26
You may also be interested by these reports :
10/09/26
After an incredible 184% share price run from November 2023 to February 2026, UCB’s shares have lost c.28% of their value. This is largely because of ...

09/09/26
The mid-to-long term targets announced on Capital Markets Day yesterday, despite being commendable, could not excite investors. This is because ...

08/09/26
The last one week’s string of R&D failures may raise concerns around Novartis’s prospects beyond 2030, though they may not impact the mid-term ...

04/09/26
While we have tweaked our earnings estimates slightly higher, the decline in our target price is owing to the removal of a peer which was skewing the ...

EXECUTIVE SUMMARY

Updates Pension Risks
Target & Opinion Governance & Management
Business & Trends Graphics : Momentum
Money Making Graphics : MACD & Volumes
Debt Graphics : Sensitivities
Valuation Sector: Performance
DCF Sector: Key data
NAV/SOTP Sector: Ratios & Valorisation
Worth knowing Sector: Peers
Financials Sector: Analysis

CONFLICTS OF INTEREST

AlphaValue does not have nor seek any business with companies covered in AlphaValue Research paid by subscription. As a result, investors can be confident that there is no conflict of interest that could affect the objectivity of AlphaValue Research.

Corporate broking NO
Trading in corporate shares NO
Analyst ownership NO
Advising of corporate (strategy, marketing, debt, etc) NO
Research paid for by corporate NO
Provision of corporate access paid for by corporate NO
Link between and a banking entity NO
Brokerage activity at AlphaValue NO